In 1990, Pfizer and CalBio subsidiary MetaBio abandoned GLP-1 drug development despite showing efficacy and holding patents. Pfizer misjudged the market for injectable diabetes drugs. CalBio redirected focus to a heart failure treatment. This decision preceded successful GLP-1 development by other companies by a decade. Novo Nordisk later succeeded with GLP-1 after research starting in 1992.